Advertisement

American Journal of Cardiovascular Drugs

, Volume 18, Issue 2, pp 75–82 | Cite as

Does Coenzyme Q10 Supplementation Mitigate Statin-Associated Muscle Symptoms? Pharmacological and Methodological Considerations

  • Beth A. Taylor
Review Article

Abstract

Statin drugs markedly reduce low-density lipoprotein cholesterol and consequently the incidence of cardiac events. In approximately 5–10% of adults, these drugs are associated with a range of muscle side effects such as muscle pain, cramping and weakness. Reduction in mitochondrial coenzyme Q10 (CoQ10), or ubiquinone, has been proposed as a mechanism for these statin-associated muscle symptoms (SAMS), and thus various formulations of CoQ10 are marketed and consumed for the prevention and treatment of SAMS. However, data supporting the efficacy of CoQ10 are equivocal, with some studies showing that CoQ10 supplementation reduces the incidence and severity of SAMS and others finding no beneficial effects of supplementation. Methodological and pharmacological issues may confound interpretation of data on this topic. For example, many patients who report SAMS, such as those who have been enrolled in previous CoQ10 studies, may be experiencing non-specific (non-statin-associated) muscle pain. In addition, the effectiveness of oral CoQ10 supplementation to increase mitochondrial CoQ10 in human skeletal muscle is not well established. This manuscript will critically evaluate the published data on the efficacy of CoQ10 supplements in the prevention and treatment of SAMS.

Notes

Compliance with Ethical Standards

Disclosures

Dr. Taylor received research support from Regeneron, Inc. and served on the Amgen Pharmacovigilance Monitoring Board.

Funding

No external funding was used in the preparation of this manuscript.

References

  1. 1.
    Prescription cholesterol-lowering drug use in adults. https://www.cdc.gov/nchs/data/databriefs/db177.pdf. Accessed July 2017.
  2. 2.
    Pedersen TR, Kjekshus J, Berg K, Scandinavian Simvastatin Survival Study Group, et al. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344:1383–9.CrossRefGoogle Scholar
  3. 3.
    Downs JR, Clearfield M, Weis S, Whitney E, Shapiro DR, Beere PA, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA. 1998;279:1615–22.CrossRefPubMedGoogle Scholar
  4. 4.
    Pencina MJ, Navar-Boggan AM, D’Agostino RBS, Williams K, Neely B, Sniderman AD, et al. Application of new cholesterol guidelines to a population-based sample. N Engl J Med. 2014;370:1422–31.CrossRefPubMedGoogle Scholar
  5. 5.
    Cham S, Evans MA, Denenberg JO, Golomb BA. Statin-associated muscle-related adverse effects: a case series of 354 patients. Pharmacotherapy. 2010;30:541–53.CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Sewright KA, Clarkson PM, Thompson PD. Statin myopathy: incidence, risk factors, and pathophysiology. Curr Atheroscler Rep. 2007;9:389–96.CrossRefPubMedGoogle Scholar
  7. 7.
    Parker BA, Capizzi JA, Grimaldi AS, Clarkson PM, Cole SM, Keadle J, et al. Effect of statins on skeletal muscle function. Circulation. 2013;127:96–103.CrossRefPubMedGoogle Scholar
  8. 8.
    Bruckert E, Hayem G, Dejager S, Yau C, Begaud B. Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients–the PRIMO study. Cardiovasc Drugs Ther. 2005;19:403–14.CrossRefPubMedGoogle Scholar
  9. 9.
    Bolego C, Baetta R, Bellosta S, Corsini A, Paoletti R. Safety considerations for statins. Curr Opin Lipidol. 2002;13:637–44.CrossRefPubMedGoogle Scholar
  10. 10.
    Rosenson RS, Baker SK, Jacobson TA, Kopecky SL, Parker BA, The National Lipid Association’s Muscle Safety Expert Panel. An assessment by the Statin Muscle Safety Task Force. update. J Clin Lipidol. 2014;2014(8):S58–71.Google Scholar
  11. 11.
    Pittman DG, Chen W, Bowlin SJ, Foody JM. Adherence to statins, subsequent healthcare costs, and cardiovascular hospitalizations. Am J Cardiol. 2011;107:1662–6.CrossRefPubMedGoogle Scholar
  12. 12.
    Franklin JM, Krumme AA, Tong AY, Shrank WH, Matlin OS, Brennan TA, et al. Association between trajectories of statin adherence and subsequent cardiovascular events. Pharmacoepidemiol Drug Saf. 2015;24:1105–13.CrossRefPubMedGoogle Scholar
  13. 13.
    Serban MC, Colantonio LD, Manthripragada AD, Monda KL, Bittner VA, Banach M, et al. Statin intolerance and risk of coronary heart events and all-cause mortality following myocardial infarction. J Am Coll Cardiol. 2017;69:1386–95.CrossRefPubMedGoogle Scholar
  14. 14.
    Zhang H, Plutzky J, Shubina M, Turchin A. Continued Statin prescriptions after adverse reactions and patient outcomes: a cohort study. Ann Intern Med. 2017;167:221–7.CrossRefPubMedGoogle Scholar
  15. 15.
    Graham JH, Sanchez RJ, Saseen JJ, Mallya UG, Panaccio MP, Evans MA. Clinical and economic consequences of statin intolerance in the United States: results from an integrated health system. J Clin Lipidol. 2017;11:70–9.CrossRefPubMedGoogle Scholar
  16. 16.
    Wei MY, Ito MK, Cohen JD, Brinton EA, Jacobson TA. Predictors of statin adherence, switching, and discontinuation in the USAGE survey: understanding the use of statins in America and gaps in patient education. J Clin Lipidol. 2013;7:472–83.CrossRefPubMedGoogle Scholar
  17. 17.
    Taylor BA, Thompson PD. Muscle-related side-effects of statins: from mechanisms to evidence-based solutions. Curr Opin Lipidol. 2015;26:221–7.CrossRefPubMedGoogle Scholar
  18. 18.
    Bouitbir J, Charles AL, Rasseneur L, Dufour S, Piquard F, Geny B, et al. Atorvastatin treatment reduces exercise capacities in rats: involvement of mitochondrial impairments and oxidative stress. J Appl Physiol. 1985;2011(111):1477–83.Google Scholar
  19. 19.
    Bouitbir J, Singh F, Charles AL, Schlagowski AI, Bonifacio A, Echaniz-Laguna A, et al. Statins trigger mitochondrial reactive oxygen species-induced apoptosis in glycolytic skeletal muscle. Antioxid Redox Signal. 2016;24:84–98.CrossRefPubMedGoogle Scholar
  20. 20.
    Mallinson JE, Marimuthu K, Murton A, Selby A, Smith K, Constantin-Teodosiu D, et al. Statin myalgia is not associated with reduced muscle strength, mass or protein turnover in older male volunteers, but is allied with a slowing of time to peak power output, insulin resistance and differential muscle mRNA expression. J Physiol. 2015;593:1239–57.CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Hubal MJ, Reich KA, De Biase A, Bilbie C, Clarkson PM, Hoffman EP, et al. Transcriptional deficits in oxidative phosphorylation with statin myopathy. Muscle Nerve. 2011;44:393–401.PubMedGoogle Scholar
  22. 22.
    Mikus CR, Boyle LJ, Borengasser SJ, Oberlin DJ, Naples SP, Fletcher J, et al. Simvastatin impairs exercise training adaptations. J Am Coll Cardiol. 2013;62:709–14.CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Chung HR, Vakil M, Munroe M, Parikh A, Meador BM, Wu PT, et al. The impact of exercise on statin-associated skeletal muscle myopathy. PLoS One. 2016;11:e0168065.CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Banach M, Serban C, Sahebkar A, Ursoniu S, Rysz J, Muntner P, et al. Effects of coenzyme Q10 on statin-induced myopathy: a meta-analysis of randomized controlled trials. Mayo Clin Proc. 2015;90:24–34.CrossRefPubMedGoogle Scholar
  25. 25.
    Deichmann RE, Lavie CJ, Asher T, DiNicolantonio JJ, O’Keefe JH, Thompson PD. The interaction between statins and exercise: mechanisms and strategies to counter the musculoskeletal side effects of this combination therapy. Ochsner J. 2015;15:429–37.PubMedPubMedCentralGoogle Scholar
  26. 26.
    Marcoff L, Thompson PD. The role of coenzyme Q10 in statin-associated myopathy: a systematic review. J Am Coll Cardiol. 2007;49:2231–7.CrossRefPubMedGoogle Scholar
  27. 27.
    Molyneux SL, Young JM, Florkowski CM, Lever M, George PM. Coenzyme Q10: is there a clinical role and a case for measurement? Clin Biochem Rev. 2008;29:71–82.PubMedPubMedCentralGoogle Scholar
  28. 28.
    Saini R. Coenzyme Q10: the essential nutrient. J Pharm Bioallied Sci. 2011;3:466–7.CrossRefPubMedPubMedCentralGoogle Scholar
  29. 29.
    Banach M, Serban C, Ursoniu S, Rysz J, Muntner P, Toth PP, et al. Statin therapy and plasma coenzyme Q10 concentrations–a systematic review and meta-analysis of placebo-controlled trials. Pharmacol Res. 2015;99:329–36.CrossRefPubMedGoogle Scholar
  30. 30.
    Paiva H, Thelen KM, Van Coster R, Smet J, De Paepe B, Mattila KM, et al. High-dose statins and skeletal muscle metabolism in humans: a randomized, controlled trial. Clin Pharmacol Ther. 2005;78:60–8.CrossRefPubMedGoogle Scholar
  31. 31.
    Larsen S, Stride N, Hey-Mogensen M, Hansen CN, Bang LE, Bundgaard H, et al. Simvastatin effects on skeletal muscle: relation to decreased mitochondrial function and glucose intolerance. J Am Coll Cardiol. 2013;61:44–53.CrossRefPubMedGoogle Scholar
  32. 32.
    Asping M, Stride N, Sogaard D, Dohlmann TL, Helge JW, Dela F, et al. The effects of 2 weeks of statin treatment on mitochondrial respiratory capacity in middle-aged males: the LIFESTAT study. Eur J Clin Pharmacol. 2017;73:679–87.CrossRefPubMedGoogle Scholar
  33. 33.
    Caso G, Kelly P, McNurlan MA, Lawson WE. Effect of coenzyme q10 on myopathic symptoms in patients treated with statins. Am J Cardiol. 2007;99:1409–12.CrossRefPubMedGoogle Scholar
  34. 34.
    Young JM, Florkowski CM, Molyneux SL, McEwan RG, Frampton CM, George PM, et al. Effect of coenzyme Q(10) supplementation on simvastatin-induced myalgia. Am J Cardiol. 2007;100:1400–3.CrossRefPubMedGoogle Scholar
  35. 35.
    Bookstaver DA, Burkhalter NA, Hatzigeorgiou C. Effect of coenzyme Q10 supplementation on statin-induced myalgias. Am J Cardiol. 2012;110:526–9.CrossRefPubMedGoogle Scholar
  36. 36.
    Bogsrud MP, Langslet G, Ose L, Arnesen KE, Sm Stuen MC, Malt UF, et al. No effect of combined coenzyme Q10 and selenium supplementation on atorvastatin-induced myopathy. Scand Cardiovasc J. 2013;47:80–7.CrossRefPubMedGoogle Scholar
  37. 37.
    Fedacko J, Pella D, Fedackova P, Hanninen O, Tuomainen P, Jarcuska P, et al. Coenzyme Q(10) and selenium in statin-associated myopathy treatment. Can J Physiol Pharmacol. 2013;91:165–70.CrossRefPubMedGoogle Scholar
  38. 38.
    Deichmann RE, Lavie CJ, Dornelles AC. Impact of coenzyme Q-10 on parameters of cardiorespiratory fitness and muscle performance in older athletes taking statins. Phys Sportsmed. 2012;40:88–95.CrossRefPubMedGoogle Scholar
  39. 39.
    Skarlovnik A, Janic M, Lunder M, Turk M, Sabovic M. Coenzyme Q10 supplementation decreases statin-related mild-to-moderate muscle symptoms: a randomized clinical study. Med Sci Monit. 2014;20:2183–8.CrossRefPubMedPubMedCentralGoogle Scholar
  40. 40.
    Taylor BA, Lorson L, White CM, Thompson PD. A randomized trial of coenzyme Q10 in patients with confirmed statin myopathy. Atherosclerosis. 2015;238:329–35.CrossRefPubMedGoogle Scholar
  41. 41.
    Buettner C, Greenman RL, Ngo LH, Wu JS. Effects of coenzyme Q10 on skeletal muscle oxidative metabolism in statin users assessed using 31P magnetic resonance spectroscopy: a randomized controlled study. J Nat Sci. 2016;2:e212.PubMedPubMedCentralGoogle Scholar
  42. 42.
    Toth S, Sajty M, Pekarova T, Mughees A, Stefanic P, Katz M, et al. Addition of omega-3 fatty acid and coenzyme Q10 to statin therapy in patients with combined dyslipidemia. J Basic Clin Physiol Pharmacol. 2017;28:327–36.CrossRefPubMedGoogle Scholar
  43. 43.
    Mancini GB, Baker S, Bergeron J, Fitchett D, Frohlich J, Genest J, et al. Diagnosis, prevention, and management of statin adverse effects and intolerance: canadian Consensus Working Group update (2016). Can J Cardiol. 2016;32:S35–65.CrossRefPubMedGoogle Scholar
  44. 44.
    Clarke TC, Black LI, Stussman BJ, Barnes PM, Nahin RL. Trends in the use of complementary health approaches among adults: United States, 2002-2012. Natl Health Stat Report. 2015;79:1–16.Google Scholar
  45. 45.
    Coenzyme Q10 market size to reach $1bn by 2024, to witness gain above 10% CAGR: Global Market Insights Inc. https://globenewswire.com/news-release/2016/09/01/868768/0/en/Coenzyme-Q10-Market-size-to-reach-1bn-by-2024-to-witness-gain-above-10-CAGR-Global-Market-Insights-Inc.html. Accessed July 2017.
  46. 46.
    Nissen SE, Stroes E, Dent-Acosta RE, Rosenson RS, Lehman SJ, Sattar N, et al. Efficacy and tolerability of evolocumab vs ezetimibe in patients with muscle-related statin intolerance: the GAUSS-3 randomized clinical trial. JAMA. 2016;315:1580–90.CrossRefPubMedGoogle Scholar
  47. 47.
    Ganga HV, Slim HB, Thompson PD. A systematic review of statin-induced muscle problems in clinical trials. Am Heart J. 2014;168:6–15.CrossRefPubMedGoogle Scholar
  48. 48.
    Tobert JA, Newman CB. The nocebo effect in the context of statin intolerance. J Clin Lipidol. 2016;10:739–47.CrossRefPubMedGoogle Scholar
  49. 49.
    Sever P, Gupta A, Thompson D, Whitehouse A, Collier T, Dahlof B, et al. Lbos 01-04 the true incidence of statin-related adverse events in hypertensive patients revealed by comparison of blinded and un-blinded use of statin in the Anglo-Scandinavian Cardiac Outcomes Trial (Ascot). J Hypertens. 2016;34:e547–8.CrossRefGoogle Scholar
  50. 50.
    Rosenson RS, Miller K, Bayliss M, Sanchez RJ, Baccara-Dinet MT, Chibedi-De-Roche D, et al. The Statin-Associated Muscle Symptom Clinical Index (SAMS-CI): revision for clinical use, content validation, and inter-rater reliability. Cardiovasc Drugs Ther. 2017;31:179–86.CrossRefPubMedPubMedCentralGoogle Scholar
  51. 51.
    Taylor BA, Sanchez RJ, Jacobson TA, Chibedi-De-Roche D, Manvelian G, Baccara-Dinet MT, et al. Application of the Statin-Associated Muscle Symptoms-Clinical Index to a randomized trial on statin myopathy. JACC. 2017;70:1680–1.CrossRefPubMedGoogle Scholar
  52. 52.
    Shults CW, Flint Beal M, Song D, Fontaine D. Pilot trial of high dosages of coenzyme Q10 in patients with Parkinson’s disease. Exp Neurol. 2004;188:491–4.CrossRefPubMedGoogle Scholar
  53. 53.
    Bhagavan HN, Chopra RK. Plasma coenzyme Q10 response to oral ingestion of coenzyme Q10 formulations. Mitochondrion. 2007;7:S78–88.CrossRefPubMedGoogle Scholar
  54. 54.
    Nuku K, Matsuoka Y, Yamagishi T, Miyawaki H, Sato K. Safety assessment of PureSorb-Q40 in healthy subjects and serum coenzyme Q10 level in excessive dosing. J Nutr Sci Vitaminol (Tokyo). 2007;53:198–206.CrossRefPubMedGoogle Scholar
  55. 55.
    Kon M, Kimura F, Akimoto T, Tanabe K, Murase Y, Ikemune S, et al. Effect of coenzyme Q10 supplementation on exercise-induced muscular injury of rats. Exerc Immunol Rev. 2007;13:76–88.PubMedGoogle Scholar
  56. 56.
    Kamzalov S, Sumien N, Forster MJ, Sohal RS. Coenzyme Q intake elevates the mitochondrial and tissue levels of coenzyme Q and alpha-tocopherol in young mice. J Nutr. 2003;133:3175–80.CrossRefPubMedGoogle Scholar
  57. 57.
    Seachrist JL, Loi CM, Evans MG, Criswell KA, Rothwell CE. Roles of exercise and pharmacokinetics in cerivastatin-induced skeletal muscle toxicity. Toxicol Sci. 2005;88:551–61.CrossRefPubMedGoogle Scholar
  58. 58.
    Westwood FR, Bigley A, Randall K, Marsden AM, Scott RC. Statin-induced muscle necrosis in the rat: distribution, development, and fibre selectivity. Toxicol Pathol. 2005;33(2):246–57.CrossRefPubMedGoogle Scholar
  59. 59.
    Piette AB, Dufresne SS, Frenette J. A short-term statin treatment changes the contractile properties of fast-twitch skeletal muscles. BMC Musculoskelet Disord. 2016;17:449.CrossRefPubMedPubMedCentralGoogle Scholar
  60. 60.
    Obayashi H, Nezu Y, Yokota H, Kiyosawa N, Mori K, Maeda N, et al. Cerivastatin induces type-I fiber-, not type-II fiber-, predominant muscular toxicity in the young male F344 rats. J Toxicol Sci. 2011;36:445–52.CrossRefPubMedGoogle Scholar
  61. 61.
    Sinzinger H, O’Grady J. Professional athletes suffering from familial hypercholesterolaemia rarely tolerate statin treatment because of muscular problems. Br J Clin Pharmacol. 2004;57:525–8.CrossRefPubMedPubMedCentralGoogle Scholar
  62. 62.
    Parker BA, Augeri AL, Capizzi JA, Ballard KD, Troyanos C, Baggish AL, et al. Effect of statins on creatine kinase levels before and after a marathon run. Am J Cardiol. 2012;109:282–7.CrossRefPubMedGoogle Scholar
  63. 63.
    Thompson PD, Zmuda JM, Domalik LJ, Zimet RJ, Staggers J, Guyton JR. Lovastatin increases exercise-induced skeletal muscle injury. Metabolism. 1997;46:1206–10.CrossRefPubMedGoogle Scholar
  64. 64.
    Muraki A, Miyashita K, Mitsuishi M, Tamaki M, Tanaka K, Itoh H. Coenzyme Q10 reverses mitochondrial dysfunction in atorvastatin-treated mice and increases exercise endurance. J Appl Physiol. 1985;2012(113):479–86.Google Scholar
  65. 65.
    El-Ganainy SO, El-Mallah A, Abdallah D, Khattab MM, Mohy El-Din MM, El-Khatib AS. Elucidation of the mechanism of atorvastatin-induced myopathy in a rat model. Toxicology. 2016;359–360:29–38.CrossRefPubMedGoogle Scholar
  66. 66.
    Cooke M, Iosia M, Buford T, Shelmadine B, Hudson G, Kerksick C, et al. Effects of acute and 14-day coenzyme Q10 supplementation on exercise performance in both trained and untrained individuals. J Int Soc Sports Nutr. 2008;5:2783–8.CrossRefGoogle Scholar
  67. 67.
    Zhou S, Zhang Y, Davie A, Marshall-Gradisnik S, Hu H, Wang J, et al. Muscle and plasma coenzyme Q10 concentration, aerobic power and exercise economy of healthy men in response to four weeks of supplementation. J Sports Med Phys Fitness. 2005;45:337–46.PubMedGoogle Scholar
  68. 68.
    Morioka TY, Lee AJ, Bertisch S, Buettner C. Vitamin D status modifies the association between statin use and musculoskeletal pain: a population based study. Atherosclerosis. 2015;238:77–82.CrossRefPubMedGoogle Scholar
  69. 69.
    Taylor B, Lorson L, White M, Thompson PD. Low vitamin D does not predict statin-associated muscle symptoms but is associated with transient increases in muscle damage and pain. Atherosclerosis. 2017;256:100–4.CrossRefPubMedGoogle Scholar
  70. 70.
    Michalska-Kasiczak M, Sahebkar A, Mikhailidis DP, Rysz J, Muntner P, Toth PP, et al. Analysis of vitamin D levels in patients with and without statin-associated myalgia - a systematic review and meta-analysis of 7 studies with 2420 patients. Int J Cardiol. 2015;178:111–6.CrossRefPubMedGoogle Scholar
  71. 71.
    Schirris TJ, Renkema GH, Ritschel T, Voermans NC, Bilos A, van Engelen BG, et al. Statin-induced myopathy is associated with mitochondrial complex III inhibition. Cell Metab. 2015;22:399–407.CrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing AG 2017

Authors and Affiliations

  1. 1.Department of KinesiologyUniversity of ConnecticutStorrsUSA
  2. 2.Division of CardiologyHenry Low Heart Center, Hartford HospitalHartfordUSA

Personalised recommendations